We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II Study of Gemcitabine, UFT and Leucovorin in Patients with Advanced Pancreatic Cancer.
- Authors
Kim, Tae Won; Kang, Hae Jin; Ahn, Jin Hee; Lee, Keehyun; Chang, Heung Moon; Kang, Yoon Koo; Lee, Jung Shin
- Abstract
The combination of gemcitabine with protracted 5-fluorouracil(5-FU) in the treatment of metastatic pancreatic cancer has shown activity with tolerable toxicity. The administration of UFT may simulate the effects of a protracted infusion of 5-FU. Patients with previously untreated metastatic or unresectable measurable pancreatic adenocarcinoma received gemcitabine (800 mg/m2 i.v., administered as an 80-min infusion on days 1, 8 and 15), UFT (200 mg/m2/day, on days 1 to 21), and oral leucovorin (90 mg/day, on days 1 to 21). Thirty patients were enrolled in this study. Five patients had partial responses, with an overall response rate of 17% (5/30), using the intent-to-treat principle (95% confidence interval (CI), 3–30%). Nine out of 25 (36%) patients experienced clinical benefit responses (95% CI; 17–55%). The median time to progression was 3.0 months, and the median overall survival was 7.2 months. The principal adverse event was neutropenia. The combination of gemcitabine, UFT, plus oral leucovorin shows significant antitumor activity and a beneficial clinical effect with an acceptable level of toxicity.
- Subjects
CANCER patients; PANCREATIC cancer; METASTASIS; COMBINATION drug therapy; CANCER treatment
- Publication
Acta Oncologica, 2002, Vol 41, Issue 7/8, p689
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/028418602321028328